Resources and events
Browse our collection of resources and explore upcoming stands and symposiums where the JARDIANCE® team will be present. We look forward to meeting you.
JARDIANCE® patient booklets
JARDIANCE® CRM patient booklet
Podcast series
Checklist for pharmacists when diagnosing and treating CKD
Advertorial on the role of pharmacists in diagnosing and treating CKD
Sick Day Rules
JARDIANCE® Initiation & Management guide for T2D, CHF and CKD
Identify patients who could benefit from JARDIANCE®
Full On-Demand Recording: Watch Dr Aled Williams and Beverley Bostock discuss the key role of primary care in addressing early CKD to prevent CVD
Highlight Summary Video: Watch Yassir Javaid discussing the importance of early use of SGLT2i for a patients with Type 2 diabetes with high cardiovascular risk
Full On-Demand Recording: Watch Dr Yassir Javaid and Judy Winter, exploring the importance of early SGLT2i use in managing cardiovascular risk in Type 2 diabetes.
Watch Dr Janaka Karalliedde discuss cardio renal metabolic conditions and the EMPA-REG OUTCOME trial
Full On-Demand Recording: Watch experts Sonia Willis and Dr Eimear Darcy explore optimising the management of type 2 diabetes and empowering patients to improve adherence.
Summary Video: Watch Dr Sarah Jarvis and Professor Smeeta Sinha discuss diagnosis and management of chronic kidney disease
Full Recording: Watch Dr Sarah Jarvis and Professor Smeeta Sinha discuss diagnosis and management of chronic kidney disease
Watch Dr Jarvis and Dr Javaid discuss NICE guidance updates (NG28) and the positioning of SGLT2 inhibitors
Watch Dr Jarvis and Dr Javaid discuss which patients may be suitable for empagliflozin treatment
Watch Dr Jarvis and Dr Javaid discuss the EMPA-REG OUTCOME trial: participants and CV mortality outcome
21st National Primary Care Diabetes & Obesity (PCDO) Society Conference
PC-GB-110623 V5 | November 2025
The content on this website is in relation to adult patients.
Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.
Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing JARDIANCE®.
- JARDIANCE® (empagliflozin) UK Summary of Product Characteristics (SmPC). Available at:
http://www.medicines.org.uk/emc/medicine/28973.
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes1
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
PC-GB-109995 V4 | October 2025